Transfusion-related acute lung injury: reports to the French Hemovigilance Network 2007 through 2008

• Published in: Transfusion (Philadelphia, Pa.) Pa.), 2011-10, Vol.51 (10), p.2102-2110
• Main Authors: Ozier, Yves, Muller, Jean-Yves, Mertes, Paul-Michel, Renaudier, Philippe, Aguilon, Philippe, Canivet, Nathalie, Fabrigli, Patrick, Rebibo, Danielle, Tazerout, Mahdi, Trophilme, Catherine, Willaert, Béatrice, Caldani, Cyril
• Format: Article
• Language: English
• Subjects: Acute Lung Injury - epidemiology; Acute Lung Injury - etiology; Acute Lung Injury - immunology; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Biological and medical sciences; Blood Component Removal; Blood Component Transfusion - adverse effects; Blood Component Transfusion - statistics & numerical data; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis; Emergency and intensive respiratory care; France - epidemiology; HLA Antigens - immunology; Humans; Incidence; Intensive care medicine; Isoantibodies - blood; Medical sciences; Population Surveillance; Prospective Studies; Transfusions. Complications. Transfusion reactions. Cell and gene therapy
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1111/j.1537-2995.2011.03073.x

BACKGROUND: Transfusion‐related acute lung injury (TRALI) is a major cause of transfusion‐related mortality and morbidity. Epidemiologic studies using data from national transfusion schemes can help achieve a better understanding of TRALI incidence. STUDY DESIGN AND METHODS: A multidisciplinary working group analyzed TRALI cases extracted from the French Hemovigilance Network Database (2007‐2008). All notified cases were reviewed for diagnosis. Those meeting the Canadian Consensus Conference criteria for TRALI were classified according to imputability to transfusion and clinical severity. Patient data (clinical characteristics, number and types of products transfused, and serology results) were obtained. RESULTS: There were 62 TRALI cases and 23 possible TRALI cases during the 2‐year period. An immune‐mediated mechanism was identified in 30 of 50 TRALI cases with complete serology. TRALI was considered to be the cause of death in 7.1% of patients and might have contributed to death in an additional 9.4% of TRALI or possible TRALI patients. Occurrence ranked high in obstetrics (15%), after surgery (34%), and in hematologic malignancies (21%). Single‐donor high‐plasma‐volume components were involved in half of the cases where the implicated blood product could be determined and carried the highest risk per component (1:31,000 for single‐donor fresh‐frozen plasma units and apheresis platelet [PLT] concentrates, and 1:173,000 for red blood cells). No incident could be definitively related to the transfusion of solvent/detergent‐treated pooled plasma (>200,000 units transfused), nor to pooled PLT concentrates. CONCLUSION: The proportion of TRALI cases related to plasma‐rich components was lower than previously described.